静脉注射丙种球蛋白无反应性川崎病的高危因素分析

doi:10.3760/cma.j.issn.1007-1245.2023.10.006

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (10): 1358-1360.DOI: 10.3760/cma.j.issn.1007-1245.2023.10.006

静脉注射丙种球蛋白无反应性川崎病的高危因素分析

杨成洋范雪徐明国

汕头大学医学院，汕头　515000

收稿日期:2022-12-09 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: 徐明国，Email：18938690175@163.com

Risk factors of children with Kawasaki disease resistant to intravenous immunoglobulin

Yang Chengyang, Fan Xue, Xu Mingguo

Medical College, Shantou University, Shantou 515000, China

Received:2022-12-09 Online:2023-05-15 Published:2023-05-16
Contact: Xu Mingguo, Email: 18938690175@163.com

摘要/Abstract

摘要：

川崎病是一种好发于儿童的急性全身性血管炎性疾病。目前，大剂量静脉注射丙种球蛋白联合口服阿司匹林是川崎病的标准治疗方案，但临床上存在一部分对静脉注射丙种球蛋白不敏感的病例。此类患者容易形成冠状动脉动病变，严重时可能导致心肌梗死和死亡。本文主要综述静脉注射丙种球蛋白无反应性川崎病的相关高危因素。

关键词:

川崎病, 高危因素, 儿童

Abstract:

Kawasaki disease is an acute systemic vasculitic disease that tends to occur in children. At present, high-dose intravenous immunoglobulin combined with oral aspirin is the standard treatment for Kawasaki disease, but some cases are not sensitive to intravenous immunoglobulin clinically. Such patients are prone to coronary artery lesions, which may lead to myocardial infarction and death in severe cases. This article mainly reviews the risk factors of children with Kawasaki disease resistant to intravenous immunoglobulin.

Key words:

Kawasaki disease, Risk factors, Children

杨成洋范雪徐明国.

静脉注射丙种球蛋白无反应性川崎病的高危因素分析 [J]. 国际医药卫生导报, 2023, 29(10): 1358-1360.

Yang Chengyang, Fan Xue, Xu Mingguo.

Risk factors of children with Kawasaki disease resistant to intravenous immunoglobulin [J]. International Medicine and Health Guidance News, 2023, 29(10): 1358-1360.

参考文献

[1] Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [J].Arerugi, 1967, 16(3): 178-222.
[2] Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007 [J]. Pediatr Infect Dis J, 2010, 29(6): 483-488. DOI: 10.1097/INF.0b013e3181cf8705.
[3] Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients [J]. Circulation, 1996, 94(6):1379-1385. DOI: 10.1161/01.cir.94.6.1379.
[4] Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin [J]. N Engl J Med, 1986, 315(6):341-347. DOI: 10.1056/NEJM198608073150601.
[5] Orenstein JM, Shulman ST, Fox LM, et al. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study [J]. PLoS One, 2012, 7(6): e38998. DOI: 10.1371/journal.pone.0038998.
[6] Rowley AH, Baker SC, Shulman ST, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease [J]. J Infect Dis, 2011, 203(7):1021-1030. DOI: 10.1093/infdis/jiq136.
[7] McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of kawasaki disease: a scientific statement for health professionals from the American Heart Association [J]. Circulation, 2017, 135(17):e927-e999. DOI: 10.1161/CIR.0000000000000484.
[8] Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease [J]. Pediatr Infect Dis J, 2013, 32(8):e319-e323. DOI: 10.1097/INF.0b013e31828e887f.
[9] Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group [J]. Pediatr Infect Dis J, 1998, 17(12): 1144-1148. DOI: 10.1097/00006454-199812000-00009.
[10] Wallace CA, French JW, Kahn SJ, et al. Initial intravenous gammaglobulin treatment failure in Kawasaki disease [J]. Pediatrics, 2000, 105(6): E78. DOI: 10.1542/peds.105.6.e78.
[11] 王永清,曹晓军. 静脉注射丙种球蛋白无反应型川崎病的诊治现状[J]. 中华儿科杂志,2005,43(3):226-228. DOI: 10.3760/j.issn:0578-1310.2005.03.030.
[12] 吴洁.丙种球蛋白无反应型川崎病预测评分系统的验证及血浆置换治疗川崎病269例的系统评价[D].苏州:苏州大学,2018.
[13] Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan [J]. Pediatr Infect Dis J, 2008, 27(2): 155-160. DOI: 10.1097/INF.0b013e31815922b5.
[14] 向龙,陈聪. 丙种球蛋白治疗不敏感川崎病的临床探讨[J]. 检验医学与临床,2016,13(6):826-828. DOI: 10.3969/j.issn.1672-9455.2016.06.043.
[15] Tang Y, Yan W, Sun L, et al. Prediction of intravenous immunoglobulin resistance in Kawasaki disease in an East China population [J]. Clin Rheumatol, 2016, 35(11):2771-2776. DOI: 10.1007/s10067-016-3370-2.
[16] Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease [J]. Circulation, 2006, 113(22):2606-2612. DOI: 10.1161/CIRCULATIONAHA. 105.592865.
[17] Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association [J]. Circulation, 2004, 110(17): 2747-2771. DOI: 10.1161/01.CIR. 0000145143.19711.78.
[18] 任跃,吴蓉洲,张园海,等. 静脉丙种球蛋白无反应川崎病38例临床分析[J]. 温州医学院学报,2011,41(3):259-261. DOI: 10.3969/j.issn.1000-2138.2011.03.018.
[19] 朱丹颖,宋思瑞,张晗,等. 川崎病丙种球蛋白无反应评分模型的建立与研究[J]. 国际儿科学杂志,2018,45(7):532-536,542. DOI: 10.3760/cma.j.issn.1673-4408.2018.07.010.
[20] Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset [J]. J Pediatr, 2000, 137(2):172-176. DOI: 10.1067/mpd.2000.104815.
[21] 张玉杰.血清铁蛋白对丙球无反应性川崎病的预测价值及新预测模型的建立[D].福州:福建医科大学,2020.

静脉注射丙种球蛋白无反应性川崎病的高危因素分析

Risk factors of children with Kawasaki disease resistant to intravenous immunoglobulin

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

[1]	马坤王道斌李树军. 支气管肺泡灌洗液中细胞学对儿童肺部疾病诊治研究进展 [J]. 国际医药卫生导报, 2023, 29(8): 1049-1052.
[2]	潘聪付四毛杨祝玲. 儿童克罗恩病10例生长发育状况及临床特征分析 [J]. 国际医药卫生导报, 2023, 29(8): 1111-1116.
[3]	叶国嫦高晓洁马颐姣贾实磊刘俐兵. 单中心5年先天性肾脏和尿路畸形住院构成分析 [J]. 国际医药卫生导报, 2023, 29(5): 669-675.
[4]	陈冉冉高晓洁贾实磊梁蝶. 儿童肾病综合征合并急性肾损伤的临床特点及危险因素分析 [J]. 国际医药卫生导报, 2023, 29(5): 675-679.
[5]	刘海珍. 锌制剂联合酪酸梭菌二联活菌制剂对腹泻患儿的疗效 [J]. 国际医药卫生导报, 2023, 29(5): 684-687.